Measures of exposure versus measures of rate and extent of absorption

Clinical Pharmacokinetics

Volumn 40, Issue 8, 2001, Pages 565-572

  Chen, Mei Ling ^a   Lesko, Lawrence ^a   Williams, Roger L ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNITED STATES PHARMACOPEIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; HUMAN; MEASUREMENT; PRIORITY JOURNAL; TIME;

EID: 0034863628     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140080-00001     Document Type: Article

References (49)

1. Assessment of rate of absorption in bioequivalence studies
2. max for absorption rates in investigations of bioequivalence
3. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations
4. An alternative approach for assessment of rate of absorption in bioequivalence studies
5. Bioequivalence: Performance of several measures of extent of absorption
6. Bioequivalence: Performance of several measures of rate of absorption
7. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies
8. Evaluation of different metrics as indirect measures of rate of drug absorption from extended release dosage forms at steady-state
9. Sensitive and specific determination of the equivalence of absorption rates
10. Assessment of rate of absorption in bioequivalence studies
11. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
12. Generic drugs and the prescribing physicians
13. Center of gravity of drug level curves: A model-independent parameter useful in bioavailability studies
14. Pitfalls in digital computation of the impulse response of vascular beds from indicator-dilution curves
15. Mathematical basis of point-area deconvolution method for determining in vivo input functions
16. Numerical deconvolution by least squares: Use of prescribed input functions
17. Numerical deconvolution by least squares: Use of polynomials to represent the function
18. Approximation in point-area deconvolution algorithm as mathematical basis for empirical instantaneous midpoint-input deconvolution method
19. Maximum entropy and its application to the calculation of drug absorption rate
20. Evaluation of in vivo drug release by numerical deconvolution using oral solution data as weighting function
21. Bioequivalence and therapeutic equivalence
22. Application of moment analysis in assessing rates of absorption for bioequivalence studies
23. max/AUC in investigations of bioequivalence
24. max/AUC is an effective metric in investigations of bioequivalence
25. Absorption rate vs. exposure: Which is more useful for bioequivalence testing?
26. max: An unconfounded metric for rate of absorption in single dose bioequivalence studies
27. Sensitivity of indirect metrics for assessing 'rate' in bioequivalence studies - Moving the 'goalposts' or changing the 'game'
28. Area under the curve estimation in bioequivalence studies
29. The cutoff time point of the partial area method for assessment of rate of absorption in bioequivalence studies
30. The duration of measuring partial AUCs for the assessment of bioequivalence
31. Metrics comparing simulated early concentration profiles for the determination of bioequivalence
32. An improved intercept method for the assessment of absorption rate in bioequivalence studies
33. The partial areas in assessment of rate and extent of absorption in bioequivalence studies of conventional release products: Experimental evidence
34. Truncated AUC evaluates effectively the bioequivalence of drugs with long half-lives
35. Truncated area under the curve as a measure of relative extent of bioavailability evaluation using experimental data and Monte Carlo simulation
36. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect
37. Modeling toxicity and response in carboplatin-based combination chemotherapy
38. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
39. Clinical pharmacodynamics of continuous infusion teniposide: Systemic exposure as a determinant of response in a phase I trial
40. Can severe vincristine neurotoxicity be prevented?
41. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials
42. Antibiotic dosing: Does one size fit all?
43. Mathematical examination of dual individualization principles II: The rate of bacterial eradication at the same area under the inhibitory curve (AUIC) is more rapid for ciprofloxacin than for cefmenoxime
44. Early exposure in bioequivalence: Evaluation of statistical criteria using clinical trial simulation
45. Mean apical concentration and duration in the comparative bioavailability of slowly absorbed and eliminated drug preparations